Press Releases

Biobot Analytics and Ceres Nanosciences Announce Partnership and Establishment of Wastewater-based Epidemiology Center of Excellence

February 16, 2022

Cambridge, Mass. – February 4, 2022 – Biobot Analytics, Inc. (Cambridge, MA) and Ceres Nanosciences (Manassas, VA) are pleased to announce a partnership in which Biobot will incorporate Ceres’ Nanotrap® Magnetic Virus Particles into its wastewater epidemiology platform, and be established as a Wastewater-based Epidemiology Center of Excellence.

This partnership will facilitate the integration of Ceres’ Nanotrap® Magnetic Virus Particles into Biobot’s wastewater sampling process, ultimately increasing the ease and efficiency of Biobot’s sampling practices.

“We’re thrilled to be incorporating the Nanotrap® particle technology into our sampling practices as it will help reduce processing time and increase stability and recovery” said Mariana Matus, Biobot CEO. “We are particularly excited about the possibilities of future applications for this inventive technology across targets beyond COVID-19, such as opioids and other infectious diseases. This in turn will support our ability to scale our Government and Enterprise platforms to service customers including public health departments, office buildings, and universities.”

“In addition, we are truly honored to be selected as one of the Wastewater-based Epidemiology (WBE) Centers of Excellence under the National Institutes of Health (NIH) RADx® initiative. This initiative helps to highlight the important work being done in WBE, and shows how WBE can be used to empower underrepresented and underserved populations.”

Ceres Nanosciences’ Chief Business Officer, Robbie Barbero, added, “Ceres Nanosciences and Biobot have a shared vision of providing fast and accurate monitoring of SARS-CoV-2 in wastewater in order to enable informed and timely public health decision making. And we are really excited about this partnership because our Nanotrap® technology platform is perfectly suited to support Biobot’s plans to expand into additional analytes and locales.”

About Biobot Analytics

Biobot Analytics is a global leader in wastewater epidemiology, founded with the goal of
transforming wastewater infrastructure into real-time public health observatories. Having Worked
at more than 700 locations across all 50 US states and several countries, Biobot produces actionable information from wastewater to improve the health of communities around the world. Biobot’s pioneering data platform also supports building-level monitoring for enterprise customers and minimizes business operation disruptions for seamless return-to-office plans.

Learn more about our Government and Enterprise platforms at our website, &

More information on our mission and technology is available at our website,

About Ceres Nanosciences

Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on incorporating its novel Nanotrap® particle technology into a range of diagnostic and research products and workflows. The Nanotrap® particle technology can improve diagnostic testing by capturing, concentrating, and preserving low abundance analytes from biological samples. The Nanotrap® particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, and the Commonwealth of Virginia. Learn more, including how Ceres is partnering with leading life science, bio-pharmaceutical, and diagnostic companies at

The Centers of Excellence program was funded in part by the NIH Rapid Acceleration of Diagnostics (RADx®) initiative with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. The current contract is funded from the Public Health and Social Services Emergency Fund through the Biomedical Advanced Research and Development Authority, HHS Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, under Contract No. 75N92021C00012.